NCT02958852View on ClinicalTrials.gov

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

January 2, 2025

Study Completion Date

January 15, 2025

Conditions

Breast Cancer

Interventions

DRUG

Letrozole

Daily orally

DRUG

Letrozole and atorvastatin

Daily orally

DRUG

Fulvestrant

Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.

Trial Locations (1)

221 85

Lund University Hospital, Department of Oncology, Lund

All Listed Sponsors

collaborator

South Sweden Breast Cancer Group

UNKNOWN

lead

Lund University Hospital

OTHER

NCT02958852 - A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter